HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
saprisartan potassium
structure given in first source
Also Known As:
GR 138950; GR-138950; GR138950; GR138950C; sapri-sartan potassium; 1-((3-bromo-2-(2-(((trifluoromethyl)sulfonyl)amino)phenyl)-5-benzofuranyl)methyl)-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide, potasium salt
Networked:
7
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzofurans: 26
saprisartan potassium: 7
Related Diseases
1.
Hypotension (Low Blood Pressure)
09/01/1996 - "
9. The present study demonstrated that administration of either GR138950 or captopril to pregnant ewes effectively blocked the maternal RAS, and caused hypotension and a decrease in uterine blood flow.
"
2.
Hypertension (High Blood Pressure)
09/16/1994 - "
Further studies are in progress to evaluate GR138950 in the treatment of hypertension.
"
3.
Tachycardia (Tachyarrhythmias)
11/01/1998 - "
GR138950 caused a marked reduction in blood pressure associated with immediate tachycardia in conscious RALH rats.
"
12/01/1997 - "
2. GR138950, enalapril or hydralazine caused marked reductions in blood pressure associated with immediate tachycardia in conscious RALH rats.
"
11/01/1998 - "
The tachycardia caused by GR138950 was attenuated by atenolol and was abolished by combined pretreatment with atenolol and atropine methyl nitrate.
"
12/01/1997 - "
The initial tachycardia caused by GR138950 or enalapril but not hydralazine was attenuated by L-NAME pretreatment.
"
4.
Right Ventricular Hypertrophy
11/01/1996 - "
3. Rats treated intravenously with the AT1 antagonist, GR138950C, 1 mg kg-1 day-1 rather than saline alone during 7 days of exposure to hypoxia developed less pulmonary hypertension (pulmonary arterial pressure: 21.3 +/- 1.7 vs 28.3 +/- 1.1 mmHg; P < 0.05), right ventricular hypertrophy (right/left ventricle weight ratio: 0.35 +/- 0.01 vs 0.45 +/- 0.01; P < 0.05) and pulmonary artery remodelling (abundance of thick-walled pulmonary vessels: 9.6 +/- 1.4% vs 20.1 +/- 0.9%; P < 0.05).
"
5.
Pulmonary Hypertension
11/01/1996 - "
3. Rats treated intravenously with the AT1 antagonist, GR138950C, 1 mg kg-1 day-1 rather than saline alone during 7 days of exposure to hypoxia developed less pulmonary hypertension (pulmonary arterial pressure: 21.3 +/- 1.7 vs 28.3 +/- 1.1 mmHg; P < 0.05), right ventricular hypertrophy (right/left ventricle weight ratio: 0.35 +/- 0.01 vs 0.45 +/- 0.01; P < 0.05) and pulmonary artery remodelling (abundance of thick-walled pulmonary vessels: 9.6 +/- 1.4% vs 20.1 +/- 0.9%; P < 0.05).
"
Related Drugs and Biologics
1.
Captopril (Capoten)
2.
Losartan (Cozaar)
3.
NG-Nitroarginine Methyl Ester (L-NAME)
4.
Hydralazine (Apresoline)
5.
Enalapril
6.
Atropine
7.
Atenolol (Tenormin)
8.
methyl nitrate